In the last trading session, 1.46 million shares of the Neogenomics Inc (NASDAQ:NEO) were traded, and its beta was 1.52. Most recently the company’s share price was $9.50, and it changed around -$0.22 or -2.26% from the last close, which brings the market valuation of the company to $1.22B. NEO currently trades at a discount to its 52-week high of $19.11, offering almost -101.16% off that amount. The share price’s 52-week low was $8.05, which indicates that the current value has risen by an impressive 15.26% since then. We note from Neogenomics Inc’s average daily trading volume that its 10-day average is 2.21 million shares, with the 3-month average coming to 1.42 million.
Neogenomics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 4 recommended NEO as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Neogenomics Inc is expected to report earnings per share of -0.01 for the current quarter.
Neogenomics Inc (NASDAQ:NEO) trade information
Instantly NEO has showed a red trend with a performance of -2.26% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.18 on recent trading dayincreased the stock’s daily price by 6.68%. The company’s shares are currently down -42.35% year-to-date, but still up 15.85% over the last five days. On the other hand, Neogenomics Inc (NASDAQ:NEO) is -3.46% down in the 30-day period. We can see from the shorts that 4.84 million shares have been sold at a short interest cover period of 3.23 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 47.22% from its current value. Analyst projections state that NEO is forecast to be at a low of $18 and a high of $18.
Neogenomics Inc (NEO) estimates and forecasts
The year-over-year growth rate is expected to be 11.77%, up from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 171.07M in revenue for the current quarter. 13 analysts expect Neogenomics Inc to make 182.84M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 156.24M and 164.5M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 9.49%. Forecasts for the next quarter put sales growth at 11.15%.
Neogenomics Inc earnings are expected to increase by 58.74% in 2025, but the outlook is positive 75.33% per year for the next five years.
NEO Dividends
Neogenomics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-17.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.07% of Neogenomics Inc shares, and 102.29% of them are in the hands of institutional investors. The stock currently has a share float of 103.39%. Neogenomics Inc stock is held by 354.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 15.5612% of the shares, which is about 19.67 million shares worth $272.82 million.
VANGUARD GROUP INC, with 11.1716% or 14.12 million shares worth $195.87 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 7.94 shares worth $75.39 million, making up 6.17% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 3.95 shares worth around $37.54 million, which represents about 3.07% of the total shares outstanding.
